Información:
Error:
ID
45884
Descripción
Principal Investigator: Timothy Chan, MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000980 Patients with non-small cell lung cancer were treated with pembrolizumab. Their tumors and matched normal blood were sequenced.
Link
Palabras clave
Versiones (1)
- 18/11/23 18/11/23 - Simon Heim
Titular de derechos de autor
Timothy Chan, MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Subido en
18 de noviembre de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000980 PD-1 Blockade in Non-Small Cell Lung Cancer
This subject phenotype table contains de-identified Subject ID, patient's cohort in current study, tumor histology, age, sex, smoking status and pack years, PD-L1 protein expression, prior courses of cytotoxic chemotherapy, pembrolizumab dose and administration, progression free survival, best overall response to pembrolizumab, durable clinical benefit and molecular smoking signature.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and affection status for case control status of the subject. All subjects are patients with non-small cell lung cancer.
- This subject sample mapping data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This sample attributes table contains de-identified sample ID, body site where sample was collected, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage, type of tumor treatment, and names of the center which conducted genotyping and sequencing.
- This subject phenotype table contains de-identified Subject ID, patient's cohort in current study, tumor histology, age, sex, smoking status and pack years, PD-L1 protein expression, prior courses of cytotoxic chemotherapy, pembrolizumab dose and administration, progression free survival, best overall response to pembrolizumab, durable clinical benefit and molecular smoking signature.
Similar models
This subject phenotype table contains de-identified Subject ID, patient's cohort in current study, tumor histology, age, sex, smoking status and pack years, PD-L1 protein expression, prior courses of cytotoxic chemotherapy, pembrolizumab dose and administration, progression free survival, best overall response to pembrolizumab, durable clinical benefit and molecular smoking signature.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and affection status for case control status of the subject. All subjects are patients with non-small cell lung cancer.
- This subject sample mapping data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This sample attributes table contains de-identified sample ID, body site where sample was collected, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage, type of tumor treatment, and names of the center which conducted genotyping and sequencing.
- This subject phenotype table contains de-identified Subject ID, patient's cohort in current study, tumor histology, age, sex, smoking status and pack years, PD-L1 protein expression, prior courses of cytotoxic chemotherapy, pembrolizumab dose and administration, progression free survival, best overall response to pembrolizumab, durable clinical benefit and molecular smoking signature.
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
SUBJECT_ID
Item
De-identified Subject ID
string
C4684638 (UMLS CUI [1,1])
C2348585 (UMLS CUI [1,2])
C2348585 (UMLS CUI [1,2])
Cohort
Item
Patient's cohort in current study
string
C0599755 (UMLS CUI [1,1])
C0947630 (UMLS CUI [1,2])
C0947630 (UMLS CUI [1,2])
Histology
Item
Tumor histology
string
C1516204 (UMLS CUI [1,1])
Age
Item
Patient's age
text
C0001779 (UMLS CUI [1,1])
CL Item
Female (F)
C0086287 (UMLS CUI [1,1])
CL Item
Male (M)
C0086582 (UMLS CUI [1,1])
CL Item
Not applicable (NA)
C1272460 (UMLS CUI [1,1])
CL Item
Other (Oth)
CL Item
Unknown (UNK)
Smoking
Item
Self-reported smoking status
string
C1519386 (UMLS CUI [1,1])
C2700446 (UMLS CUI [1,2])
C2700446 (UMLS CUI [1,2])
Pack-years
Item
Product of number of packs per day and number of years smoked
text
C3694145 (UMLS CUI [1,1])
C4288114 (UMLS CUI [1,2])
C4288114 (UMLS CUI [1,2])
PD-L1
Item
Programmed death-ligand 1 (PD-L1) expression
string
C5781048 (UMLS CUI [1,1])
Priors
Item
Prior courses of cytotoxic chemotherapy. Combination chemotherapy counted as a single course. No patient had received prior immunotherapy.
text
C1302181 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C1521750 (UMLS CUI [2,1])
C0750729 (UMLS CUI [2,2])
C0205447 (UMLS CUI [2,3])
C1298908 (UMLS CUI [3,1])
C1514463 (UMLS CUI [3,2])
C0021083 (UMLS CUI [3,3])
C0237753 (UMLS CUI [1,2])
C1521750 (UMLS CUI [2,1])
C0750729 (UMLS CUI [2,2])
C0205447 (UMLS CUI [2,3])
C1298908 (UMLS CUI [3,1])
C1514463 (UMLS CUI [3,2])
C0021083 (UMLS CUI [3,3])
Dose (mg/kg)
Item
Dose (mg/kg)
text
C3174092 (UMLS CUI [1,1])
Sched
Item
Pembrolizumab dosed every 2 or 3 weeks as indicated.
text
C3658706 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1561548 (UMLS CUI [1,3])
C0178602 (UMLS CUI [1,2])
C1561548 (UMLS CUI [1,3])
PFS (mos)
Item
Progression free survival in months
text
C0242792 (UMLS CUI [1,1])
C0439231 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,2])
Resp
Item
Denotes best overall response to pembrolizumab
string
C2986560 (UMLS CUI [1,1])
C3658706 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C3658706 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
Durable_Clinical_Benefit
Item
Patient's clinical benefit
string
C4684590 (UMLS CUI [1,1])
Smoking_Signature
Item
Molecular smoking signature
string
C1704864 (UMLS CUI [1,1])
C0037369 (UMLS CUI [1,2])
C0037369 (UMLS CUI [1,2])
Sin comentarios